Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19025124 | 0.87 | DPP4 (0.44) | ERN1ALDH1A1DPP4 | |
| SCHEMBL3578196 | 0.86 | LMNA (0.62) | ERN1ALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL15085002 | 0.86 | DPP4 (0.46) | ERN1ALDH1A1L3MBTL1DPP4SMN1; SMN2 | |
| SCHEMBL6699503 | 0.84 | ALDH1A1 (0.57) | ERN1ALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL29771746 | 0.84 | LMNA (0.51) | ERN1ALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL29246798 | 0.84 | LMNA (0.51) | ERN1ALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL1391291 | 0.84 | ERN1 (0.41) | ERN1ALDH1A1LMNADPP4 | |
| SCHEMBL22146466 | 0.81 | KDM4E (0.41) | ERN1ALDH1A1LMNAL3MBTL1DPP4 | |
| SCHEMBL19025114 | 0.81 | ALDH1A1 (0.50) | ERN1ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL4971064 | 0.81 | ALDH1A1 (0.50) | ERN1ALDH1A1LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11266648-B2 | Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11083729-B2 | Methods of treating cancer with small molecule NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200345739-A1 | SMALL MOLECULE NF-kB INHIBITORS | ImmuneTarget, Inc. | 2020-11-05 | — | — | US | disclosed |
| CN-111417396-A | Methods of treating cancer with small molecule NF-kB inhibitors | 免疫目标公司 | 2020-07-14 | — | — | CN | disclosed |
| US-10660894-B2 | Small molecule NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3645007-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE NF-KB INHIBITORS | Immunetarget, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190142836-A1 | SMALL MOLECULE NF-kB INHIBITORS | ImmuneTarget, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10226464-B2 | Small molecule NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190040087-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-20190040087-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-10040806-B2 | Microbiocidally active benzoxaboroles | SYNGENTA PARTICIPATIONS AG (CH) | 2018-08-07 | — | — | US | disclosed |
| US-10040806-B2 | Microbiocidally active benzoxaboroles | SYNGENTA PARTICIPATIONS AG (CH) | 2018-08-07 | — | — | US | disclosed |
| WO-2017117355-A1 | 2H-CHROMENO[2,3-D]PYRIMIDINE-2,4(3H)-DIONES AS NF-KB INHIBITORS | ImmuneTarget, Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170182051-A1 | SMALL MOLECULE NF-kB INHIBITORS | IMMUNETARGET INC (US) | 2017-06-29 | — | — | US | disclosed |
| EP-3107921-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | Syngenta Participations AG (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-20160347773-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160347773-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160347773-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| WO-2015121442-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121442-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142836-A1 | SMALL MOLECULE NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | ERN1 827/4885ALDH1A1 4249/4885LMNA 762/4885 |
| US-11083729-B2 | Methods of treating cancer with small molecule NF-κB inhibitors | NFKBIA, IKBKB, RELA | ERN1 850/4885ALDH1A1 2307/4885LMNA 404/4885 |
| US-10660894-B2 | Small molecule NF-κB inhibitors | NFKBIA, RELA, NFKB2 | ERN1 778/4885ALDH1A1 3359/4885LMNA 1186/4885 |
| US-20190040087-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | MPO, BROX, MANBA | ERN1 3441/4885ALDH1A1 1549/4885LMNA 2186/4885 |
| US-10226464-B2 | Small molecule NF-κB inhibitors | NFKBIA, RELA, NFKB2 | ERN1 778/4885ALDH1A1 3359/4885LMNA 1186/4885 |
| US-20170182051-A1 | SMALL MOLECULE NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | ERN1 827/4885ALDH1A1 4249/4885LMNA 762/4885 |
| US-20160347773-A1 | MICROBIOCIDALLY ACTIVE BENZOXABOROLES | MPO, BROX, MANBA | ERN1 3441/4885ALDH1A1 1549/4885LMNA 2186/4885 |
| US-20200345739-A1 | SMALL MOLECULE NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | ERN1 827/4885ALDH1A1 4249/4885LMNA 762/4885 |
| US-11266648-B2 | Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors | NFKBIA, IKBKB, RELA | ERN1 1323/4885ALDH1A1 1886/4885LMNA 1033/4885 |
| US-10040806-B2 | Microbiocidally active benzoxaboroles | MPO, BROX, MANBA | ERN1 3441/4885ALDH1A1 1549/4885LMNA 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.